Nkarta Inc NKTX:NASDAQ

RT Quote | NASDAQ | USD
Last | 02/25/21 EST
48.80quote price arrow down-2.78 (-5.39%)
Volume
207,037
52 week range
22.46 - 79.16

...

Loading . . .

KEY STATS

  • Open52.00
  • Day High55.21
  • Day Low46.02
  • Prev Close48.80
  • 52 Week High79.16
  • 52 Week High Date12/24/20
  • 52 Week Low22.46
  • 52 Week Low Date09/02/20
  • Market Cap1.591B
  • Shares Out32.60M
  • 10 Day Average Volume0.25M
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-2.58
  • P/E (TTM)-18.92
  • Fwd P/E (NTM)-24.31
  • EBITDA (MRQ)-28.166M
  • ROE (MRQ)-
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-1,155,795.00%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Nkarta Inc News

There is no recent news for this security.

Latest NKTX News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Nkarta, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) and cell therapies to treat cancer. Its modular NK cell engineering platform allows it to generate new product candidates. The Company’s engineered CAR-NK cells generally consist of an NK cell engineered with a targeting receptor, OX40 costimulatory domain, CD3z signaling moiety, and mbIL-15. This...
Ali Behbahani M.D.
Chairman
Paul Hastings
President
Nadir Mahmood Ph.D.
Chief Financial Officer
Ralph Brandenberger Ph.D.
Vice President
Address
6000 Shoreline Court, Suite 102
South San Francisco, CA
94080
United States